BioSpace News Archive

Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease.

Magnolia Neurosciences Corporation is a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines. The company was launched by a $31 million Series A investment by Accelerator Life Science Partners in 2018 and was co-founded by world-class researchers at The University of Texas MD Anderson Cancer Center.

Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems.

Foresee Pharmaceuticals is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange（TPEx: 6576）. Foresee’s R&D efforts are focused on two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable technology with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs.

Affinia Therapeutics is an innovative gene therapy company focused on broadening the reach of gene therapy. Our proprietary Affinia Rationally-designed Therapies (ART) platform is created to address key limitations of conventional gene therapies, by developing novel capsids, novel promoters, and novel manufacturing approaches to developing gene therapies for rare and prevalent devastating diseases.

Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

Qpex Biopharma, Inc. a Shionogi Group Company, is a resistance-focused infectious disease company on a mission to make both a dramatic and sustainable improvement in patient care. Leveraging a multi-faceted approach and a deep understanding of drug resistance mechanisms, we are creating novel products and development. strategies that overcome multi-drug resistance.

Twentyeight - Seven Therapeutics is now Redona Therapeutics.

A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer.